Valeant Says Senior Executive's Departure Unrelated to Probe
- Deb Jorn left for personal reasons, according to Valeant
- `The optics of the resignation certainly do not look good'
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. said the departure of Deb Jorn, its head of U.S. dermatology products, wasn’t the result of any action taken by an ad hoc board committee that’s probing the drugmaker’s now-severed relationships with a controversial mail-order pharmacy.
“It is our understanding that Deb Jorn decided to leave Valeant for personal reasons,” the company said in a statement Thursday.